Sun Pharmaceutical Industries of Mumbai, India has entered an agreement to acquire Ranbaxy Laboratories from parent company Daiichi Sankyo, in a transaction valued at $4 billion. The combined company will be India’s largest pharmaceutical company and the world’s fifth-largest generic company, with an estimated annual revenue of $4.2 billion. The acquisition is subject to shareholder approval from both companies.
 
In January, the FDA prohibited Ranbaxy from selling drugs in the U.S. due to poor manufacturing practices, and from distributing any raw materials in the U.S. from its Toansa facility in India, including the sale of materials to other companies that distribute products in the U.S. Ranbaxy has five manufacturing facilities in India that are registered with the FDA: Paonta Sahib, Mohali, Toansa, Gurgaon and Dewas, all of which are now covered under the consent decree with the U.S. Department of Justice. 
 
According to a statement by Sun Pharma, the transaction includes $3.2 billion in stock and approximately $800 million of Ranbaxy debt. Ranbaxy shareholders are expected to own 14% of the new company and Daiichi Sankyo, will be the largest single shareholder.
                       
The acquisition will expand Sun Pharma’s global presence and manufacturing capabilities. The combined company will have 47 factories across five continents and operations in 65 countries. Dilip Shanghvi, Sun Pharma’s managing director, said, “In high-growth emerging markets, it provides a strong platform which is highly complementary to Sun Pharma’s strengths. We see tremendous growth opportunities.”